A Multi-Center, Phase 3, Double-Blind, Randomized, and Controlled Trial of KD019 vs Erlotinib in Subjects With Stage IIIB/IV Non-Small Cell Lung Cancer Who Have Progressed After First- or Second-Line Chemotherapy
Conditions
Non Small Cell Lung Cancer
What is the purpose of this trial?
Primary Outcome Measures: · Overall survival
Secondary Outcome Measures: · Progression-free survival · Number and type of adverse events related to KD019 · Objective response rate |
Participation Guidelines
- Age:
- 18 Years and older
- Gender:
- Both
Click here for detailed information about who can participate in this trial.
- Sponsor:
- Kadmon Corporation, LLC
- Dates:
- November 2012
- Last Updated:
- Study HIC#:
- 1204010034
Clinicaltrials.gov ID: Yale4409252
